| 6.83 -0.18 (-2.57%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.43 | 1-year : | 9.84 |
| Resists | First : | 7.21 | Second : | 8.43 |
| Pivot price | 6.87 |
|||
| Supports | First : | 6.45 | Second : | 5.98 |
| MAs | MA(5) : | 6.97 |
MA(20) : | 6.73 |
| MA(100) : | 6.01 |
MA(250) : | 5.57 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 73 |
D(3) : | 77.2 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 11 | Low : | 3.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ UNCY ] has closed above bottom band by 43.1%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.15 - 7.19 | 7.19 - 7.22 |
| Low: | 6.68 - 6.73 | 6.73 - 6.77 |
| Close: | 6.76 - 6.84 | 6.84 - 6.89 |
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Fri, 13 Mar 2026
Unicycive Therapeutics (NASDAQ:UNCY) Shares Down 0.4% - Here's Why - MarketBeat
Fri, 06 Mar 2026
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm - TMX Newsfile
Thu, 29 Jan 2026
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha
Thu, 29 Jan 2026
FDA sets June 27 action date for Unicycive kidney disease pill - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 39.7 (%) |
| Shares Short | 1,830 (K) |
| Shares Short P.Month | 1,600 (K) |
| EPS | -3.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.79 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.3 % |
| Return on Equity (ttm) | -102.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -1.99 |
| PEG Ratio | 0 |
| Price to Book value | 3.79 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|